#gsk — Public Fediverse posts

Halifax

Important information Halifax Share Dealing Limited. Registered in England and Wales no. 3195646. Registered Office: Trinity Road, Halifax,…
#EuropeSays #Britain #Europe #EU #GSK #BrokerOnLine
https://www.europesays.com/britain/86383/

EMA Accepts GSK’s Bexsero Booster Label Update for Single-Dose Meningitis B Vaccine in Individuals Aged 10 and Above

Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/86370/

GSK Discontinues Development of Camlipixant for Refractory Chronic Cough

GSK plc GSK has announced that it is discontinuing development of camlipixant, an investigational P2X3 receptor antagonist, for the…
#EuropeSays #Britain #Europe #EU #GSK #chroniccough #development #EPSestimates #GSKplc #ZacksInvestmentResearch
https://www.europesays.com/britain/85910/

https://www.europesays.com/britain/85910/ GSK Discontinues Development of Camlipixant for Refractory Chronic Cough #ChronicCough #development #EPSEstimates #GSK #GSKPlc #ZacksInvestmentResearch

GSK ends camlipixant RCC program after mixed results | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #BALANCEtrial #CALM-1 #CALM-2 #camlipixant #GSKplc #IBS-D #PhaseIIItrials #refractorychroniccough #SECForm6-K
https://www.europesays.com/britain/85320/

GSK to re-appoint Deloitte as external auditor | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #6-Kfiling #annualgeneralmeeting #audittender #corporategovernance #deloitte #externalauditor #GSKplc #PublicInterestEntity #statutoryaudit
https://www.europesays.com/britain/85086/

https://www.europesays.com/britain/85086/ GSK to re-appoint Deloitte as external auditor | GSK SEC Filing #6KFiling #AnnualGeneralMeeting #AuditTender #CorporateGovernance #deloitte #ExternalAuditor #GSK #GSKPlc #PublicInterestEntity #StatutoryAudit

GSK executives acquire ADSs via dividend reinvestment | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #AmericanDepositaryShares #dividendreinvestment #Form6-K #GSKADS #GSKplc #InsiderTransactions #NYSE
https://www.europesays.com/britain/84773/

https://www.europesays.com/britain/84773/ GSK executives acquire ADSs via dividend reinvestment | GSK SEC Filing #AmericanDepositaryShares #DividendReinvestment #Form6K #GSK #GSKADS #GSKPlc #InsiderTransactions #NYSE

Nuvalent director’s awards cashed out in GSK deal

SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
#EuropeSays #Britain #Europe #EU #GSK #Form4 #GlaxoSmithKline #InsiderTrading #merger #Nuvalent #NUVL #OfferPrice #SapnaSrivastava #stockoptions #tenderoffer
https://www.europesays.com/britain/83997/

https://www.europesays.com/britain/83997/ Nuvalent director’s awards cashed out in GSK deal #Form4 #GlaxoSmithKline #GSK #InsiderTrading #merger #Nuvalent #NUVL #OfferPrice #SapnaSrivastava #StockOptions #TenderOffer

Nuvalent director tenders shares in $124 GSK buyout

SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
#EuropeSays #Britain #Europe #EU #GSK #directordisposition #GlaxoSmithKlinemerger #insidertransaction #Nuvalent #NUVL #restrictedstockunits #stockoptions #tenderoffer
https://www.europesays.com/britain/83982/

https://www.europesays.com/britain/83982/ Nuvalent director tenders shares in $124 GSK buyout #DirectorDisposition #GlaxoSmithKlineMerger #GSK #InsiderTransaction #Nuvalent #NUVL #RestrictedStockUnits #StockOptions #TenderOffer

GSK Completes Nuvalent Tender Offer at $124 Per Share | NUVL SEC Filing

This Amendment No. 4 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #acquisition #merger #Nasdaqdelisting #Nuvalent #NUVL #Section251(h) #tenderoffer
https://www.europesays.com/britain/83666/

https://www.europesays.com/britain/83666/ GSK Completes Nuvalent Tender Offer at $124 Per Share | NUVL SEC Filing #$124PerShare #acquisition #GSK #merger #NasdaqDelisting #Nuvalent #NUVL #Section251(h) #TenderOffer

GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), in…
#EuropeSays #Britain #Europe #EU #GSK #approvedindications #endometrialcancers #GSKplc #Jemperli #mismatchrepair #OncologyDrug #Patients #rectalcancer #ZacksInvestmentResearch
https://www.europesays.com/britain/83022/

https://www.europesays.com/britain/83022/ GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer #ApprovedIndications #EndometrialCancers #GSK #GSKPlc #Jemperli #MismatchRepair #OncologyDrug #Patients #RectalCancer #ZacksInvestmentResearch

https://www.europesays.com/britain/82748/ GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer – July 14, 2026 #Financial #FinancialPlanning #GSK #investing #INVESTMENT #InvestmentAdvice #OnlineInvestment #OnlineStockTrading #OnlineTrading #quote #quotes #stock #StockMarket #StockQuotes #stocks

GSK leaders acquire shares via reward and dividends | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #dividendreinvestment #Form6-K #GSKplc #InsiderTransactions #LSE #ordinaryshares #sharerewardplan
https://www.europesays.com/britain/82192/

https://www.europesays.com/britain/82192/ GSK leaders acquire shares via reward and dividends | GSK SEC Filing #DividendReinvestment #Form6K #GSK #GSKPlc #InsiderTransactions #LSE #OrdinaryShares #ShareRewardPlan

GSK reports Jemperli rectal cancer trial results

GSK reported positive interim results from the AZUR-1 Phase II trial of Jemperli in dMMR/MSI-H locally advanced rectal…
#EuropeSays #Britain #Europe #EU #GSK #AZUR-1trial #Biotechnology #cancertreatment #dostarlimab #GSKplc #immunotherapy #Jemperli #Oncology #rectalcancer
https://www.europesays.com/britain/82130/

https://www.europesays.com/britain/82130/ GSK reports Jemperli rectal cancer trial results #AZUR1Trial #Biotechnology #CancerTreatment #dostarlimab #GSK #GSKPlc #immunotherapy #Jemperli #Oncology #RectalCancer

GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial

GSK’s bet on Hansoh Pharmaceutical’s antibody-drug conjugate (ADC) seems to be paying off as the drug met all…
#EuropeSays #Britain #Europe #EU #GSK #antibodydrugconjugate #China #ES-SCLC #HansohPharma #HansohPharmaceutical #Lungcancer #mainlandChina #PhaseIII #PhaseIIItrial #ris-rez
https://www.europesays.com/britain/82012/

https://www.europesays.com/britain/82012/ GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial #AntibodyDrugConjugate #China #ESSCLC #GSK #HansohPharma #HansohPharmaceutical #LungCancer #MainlandChina #PhaseIII #PhaseIIITrial #RisRez

GSK’s Jemperli meets main goal in mid-stage rectal cancer trial

GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a…
#EuropeSays #Britain #Europe #EU #GSK #AZUR-1trial #cancerdrugapproval #chemotherapyalternatives #ClinicalTrialResults #dostarlimab #immunotherapy #Jemperli #mid-stagetrial #rectalcancertrial
https://www.europesays.com/britain/81923/

GSK, Hansoh Lung Cancer Drug Hits Main Survival Goal in China Trial

British drugmaker GSK and its Chinese partner Hansoh Pharmaceutical have reported that their targeted cancer therapy, known as…
#EuropeSays #Britain #Europe #EU #GSK #antibodydrugconjugate #cancertreatmentinnovation #Chinaclinicaltrial #globaloncologypipeline #HansohPharmaceutical #Oncology #overallsurvival #Phase3trial #progression-freesurvival #ris-rez #smallcelllungcancer #targetedtherapy
https://www.europesays.com/britain/81834/

https://www.europesays.com/britain/81834/ GSK, Hansoh Lung Cancer Drug Hits Main Survival Goal in China Trial #AntibodyDrugConjugate #CancerTreatmentInnovation #ChinaClinicalTrial #GlobalOncologyPipeline #GSK #HansohPharmaceutical #Oncology #OverallSurvival #Phase3Trial #ProgressionFreeSurvival #RisRez #SmallCellLungCancer #TargetedTherapy

https://www.europesays.com/britain/81529/ GSK Velu to List Trivitron, Neuberg Diagnostics, Maxi Vision and Kauvery Hospitals in $1 Billion IPO Push Over Next Three Years #DiagnosticsChain #EyeCare #FortuneIndia #GenomicsDiagnostics #GSK #GSKVelu #HealthcareIPOs #HospitalNetwork #IndiaHealthcare #KauveryHospitals #MaxiVision #MedicalDevices #MedicalTechnology #NeubergDiagnostics #PrivateEquity #Trivitron

Nuvalent takeover: HSR waiting period cleared, $124 per share offer | GSK SEC Filing

This Amendment No. 3 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #HarmonyRow #HSRclearance #LetterofTransmittal #Nuvalent #NUVL #OffertoPurchase #tenderoffer
https://www.europesays.com/britain/80738/

https://www.europesays.com/britain/80738/ Nuvalent takeover: HSR waiting period cleared, $124 per share offer | GSK SEC Filing #$124PerShare #GSK #HarmonyRow #HSRClearance #LetterOfTransmittal #Nuvalent #NUVL #OfferToPurchase #TenderOffer

Alector loses GSK pact, repays $10.4M Hercules loan

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13…
#EuropeSays #Britain #Europe #EU #GSK #ALEC #Alector #biotech8-K #GSKcollaborationtermination #HerculesCapitalloanrepayment #INFRONT-3trial #materialdefinitiveagreement #PROGRESS-ADtrial
https://www.europesays.com/britain/79651/

https://www.europesays.com/britain/79651/ Alector loses GSK pact, repays $10.4M Hercules loan #ALEC #Alector #Biotech8K #GSK #GSKCollaborationTermination #HerculesCapitalLoanRepayment #INFRONT3Trial #MaterialDefinitiveAgreement #PROGRESSADTrial

GSK offers $124 per share to acquire Nuvalent | NUVL SEC Filing

This Amendment No. 2 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #HSRwaitingperiod #Nuvalent #NUVL #Schedule14D-9 #tenderoffer
https://www.europesays.com/britain/78877/

https://www.europesays.com/britain/78877/ GSK offers $124 per share to acquire Nuvalent | NUVL SEC Filing #$124PerShare #GSK #HSRWaitingPeriod #Nuvalent #NUVL #Schedule14D9 #TenderOffer

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. GSK plc…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #HarmonyRowAcquisitionCo. #HIVprevention #Inc. #Nuvalent #ViiVHealthcare
https://www.europesays.com/britain/73524/

https://www.europesays.com/britain/73524/ GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share #GSK #GSKPlc #HarmonyRowAcquisitionCo #HIVPrevention #Inc #Nuvalent #ViiVHealthcare

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. GSK plc…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #HarmonyRowAcquisitionCo. #HIVprevention #Inc. #Nuvalent #ViiVHealthcare
https://www.europesays.com/britain/73485/

https://www.europesays.com/britain/73485/ GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share #GSK #GSKPlc #HarmonyRowAcquisitionCo #HIVPrevention #Inc #Nuvalent #ViiVHealthcare

GSK launches $124-per-share Nuvalent tender offer | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #biopharmaM&A #cashacquisition #Form6-K #Hart-Scott-Rodino #merger #Nuvalent #Section251(h) #tenderoffer
https://www.europesays.com/britain/71723/

https://www.europesays.com/britain/71723/ GSK launches $124-per-share Nuvalent tender offer | GSK SEC Filing #$124PerShare #BiopharmaM&A #CashAcquisition #Form6K #GSK #HartScottRodino #merger #Nuvalent #Section251(h) #TenderOffer

GSK offers $124.00 cash per share for Nuvalent | NUVL SEC Filing

This Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto, this “Schedule TO”) is…
#EuropeSays #Britain #Europe #EU #GSK #$124pershare #FacilityAgreement #MergerAgreement #Nuvalent #tenderoffer
https://www.europesays.com/britain/69901/

https://www.europesays.com/britain/69901/ GSK offers $124.00 cash per share for Nuvalent | NUVL SEC Filing #$124PerShare #FacilityAgreement #GSK #MergerAgreement #Nuvalent #TenderOffer

GSK offers $124.00 per share for Nuvalent | NUVL SEC Filing

This Amendment No. 1 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (together with any…
#EuropeSays #Britain #Europe #EU #GSK #$124.00pershare #Nuvalent #NUVL #OffertoPurchase #tenderoffer
https://www.europesays.com/britain/69871/

https://www.europesays.com/britain/69871/ GSK offers $124.00 per share for Nuvalent | NUVL SEC Filing #$12400PerShare #GSK #Nuvalent #NUVL #OfferToPurchase #TenderOffer

The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK

For Immediate Release Chicago, IL – June 17, 2026 – Zacks.com announces the list of stocks featured in…
#EuropeSays #Britain #Europe #EU #GSK #GileadSciences #HIVprevention #HIVtreatment #Inc. #ZacksEquityResearch #ZacksInvestmentResearch
https://www.europesays.com/britain/64759/

https://www.europesays.com/britain/64759/ The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK #GileadSciences #GSK #HIVPrevention #HIVTreatment #Inc #ZacksEquityResearch #ZacksInvestmentResearch

Down 14% to around £19! Is now just the right time for me to capitalise on GSK’s bargain-basement share price?

Image source: GSK plc GSK’s (LSE: GSK) share price has failed to keep pace with the momentum building…
#EuropeSays #Britain #Europe #EU #GSK #Cashflow #DCF #FairValue #flowengine #pipelineprogress #shareprice #stagepipeline
https://www.europesays.com/britain/63926/

https://www.europesays.com/britain/63926/ Down 14% to around £19! Is now just the right time for me to capitalise on GSK’s bargain-basement share price? #CashFlow #DCF #FairValue #FlowEngine #GSK #PipelineProgress #SharePrice #StagePipeline

https://www.europesays.com/britain/61384/ GSK’s momelotinib receives orphan drug designation from US and EU watchdogs #Category:All #Category:CompanyNews #Category:MarketPulse #Category:MarketReport #Category:NewsAndAnnouncements #Category:Sectorial:HealthTechnology #designation #drug #from #GSK #GSK's #momelotinib #mostread_company_news #orphan #receives #watchdogs

https://www.europesays.com/britain/60762/ GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) #acquisition #CancerTherapies #ChiefExecutiveOfficerLukeMiels #GSK #HIVTreatments #LicensingAgreements #Nuvalent #Oncology #PharmaceuticalSales #Strategy